Hodgkin Lymphoma - Pipeline Review, H1 2014

Hodgkin Lymphoma - Pipeline Review, H1 2014

Feb 2014 Global Markets Direct Lymphoma207 Pages Price :
$ 2000

Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma Overview
Therapeutics Development
Pipeline Products for Hodgkin Lymphoma - Overview
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis
Hodgkin Lymphoma - Therapeutics under Development by Companies
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Hodgkin Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hodgkin Lymphoma - Products under Development by Companies
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
Seattle Genetics, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Gamida Cell Ltd.
Plexxikon Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Cell Therapeutics, Inc.
Incyte Corporation
4SC AG
Dynavax Technologies Corporation
Spectrum Pharmaceuticals, Inc.
Affimed Therapeutics AG
Actinium Pharmaceuticals, Inc.
Philogen S.p.A.
MABLife S.A.S
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Sigma-Tau Pharmaceuticals, Inc
Rhizen Pharmaceuticals SA
Immune Pharmaceuticals, Inc.
Pharmedartis GmbH
Hodgkin Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
procarbazine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
StemEx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
resminostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pralatrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-3397 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radretumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iomab-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferritarg - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-40346527 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minor Histocompatibility Antigen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pevonedistat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDX-1401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vinorelbine tartrate liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFM-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ciclopirox olamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EBV-Specific T-Lymphocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSC-678515 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lambrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genetically Modified T Cell - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-047986 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP-Specific Cytotoxic T Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Granzyme B Based Immunotoxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferritizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hodgkin Lymphoma - Recent Pipeline Updates
Hodgkin Lymphoma - Dormant Projects
Hodgkin Lymphoma - Discontinued Products
Hodgkin Lymphoma - Product Development Milestones
Featured News & Press Releases
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting
Oct 11, 2013: Seattle Genetics Highlights ADCETRIS (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma
Sep 16, 2013: Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients
Jun 24, 2013: Affimed Reports Phase I Clinical Data For Its Immunotherapy AFM13 In Relapsing/Refractory Hodgkin Lymphoma Patients
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma
Jun 10, 2013: Seattle Genetics Initiates Phase I/II Trial Of Adcetris In Combination With Bendamustine For Hodgkin Lymphoma Patients After Initial Relapse
Jun 02, 2013: Seattle Genetics Announces Presentation Of Adcetris Clinical Development Programs At ASCO Annual Meeting 2013

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products under Development for Hodgkin Lymphoma, H1 2014
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Investigation by Universities/Institutes, H1 2014
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2014
Hodgkin Lymphoma - Pipeline by Plexxikon Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2014
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014
Hodgkin Lymphoma - Pipeline by Cell Therapeutics, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2014
Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2014
Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2014
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2014
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2014
Hodgkin Lymphoma - Pipeline by MABLife S.A.S, H1 2014
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Janssen Research & Development, LLC., H1 2014
Hodgkin Lymphoma - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014
Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2014
Hodgkin Lymphoma - Pipeline by Immune Pharmaceuticals, Inc., H1 2014
Hodgkin Lymphoma - Pipeline by Pharmedartis GmbH, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014
Hodgkin Lymphoma - Dormant Projects, H1 2014
Hodgkin Lymphoma - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Hodgkin Lymphoma, H1 2014
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top